19 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
29 May 20
Vir Biotechnology and Biogen Execute Agreement to ManufactureSARS-CoV-2 Antibodies for PotentialCOVID-19 Treatment
4:06pm
(also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for escape mutants to develop.VIR-7831 has … is highly conserved, which may make it more difficult for escape mutants to develop.VIR-7832 has been engineered to have an extended half-life
8-K
EX-99.1
VIR
Vir Biotechnology Inc
12 May 20
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results
4:05pm
(also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for escape mutants to develop. VIR-7831 has … that the epitope is highly conserved, which may make it more difficult for escape mutants to develop. VIR-7831 has been engineered to have an extended half-life
8-K
EX-99.1
VIR
Vir Biotechnology Inc
11 Aug 20
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results
4:05pm
), indicating that the epitope is highly conserved, which may make it more difficult for escape mutants to develop. VIR-7831 has been engineered to enhance … that the epitope is highly conserved, which may make it more difficult for escape mutants to develop. VIR-7832 has been engineered to enhance bioavailability, have
8-K
EX-99.1
VIR
Vir Biotechnology Inc
6 May 21
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:24pm
2020, and how this mutation might evade immunity.
In February:
medRxiv posted a pre-print manuscript, “SARS-CoV-2 B.1.1.7 escape from mRNA vaccine … that maximize breadth and resistance to viral escape” (Starr, et al.), which highlighted the importance of mAbs that target the RBD, given their high
8-K
EX-99.1
VIR
Vir Biotechnology Inc
16 Sep 20
Other Events
4:07pm
drift and escape mutants INFECTED PNEUMOCYTES UNINFECTED PNEUMOCYTES Conversely, cocktails of antibodies are needed when using antibodies with a low
8-K
EX-99.1
aqr9f1
26 Mar 20
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
4:01pm
8-K
EX-99.1
54queldazbw2l58
10 Nov 20
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results
4:05pm
8-K
EX-99.2
lpj7euenr bszo
28 Jan 21
Other Events
4:05pm
8-K
EX-99.1
8qbpf y0a3r
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
8-K
EX-99.1
g9vchg 6hddk
25 Feb 21
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
4:15pm
8-K
EX-99.1
jgc8r5em eb9v9qyp
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
EX-99.1
aaqzpzh kjn01
6 Jul 20
Our mission is to create a world without infectious disease
6:32am
424B4
n7jrm0f
8 Jul 20
Prospectus supplement with pricing info
4:35pm
DRS
so82md4mz2tudy7tltm
23 Jun 20
Draft registration statement
12:00am
10-K
1bua9wyi728z7m
26 Mar 20
Annual report
4:08pm
- Prev
- 1
- Next